Marc Allaire, the newest member of the Berkeley Center for Structural Biology (BCSB) team, joined the ALS in October as beamline scientist for Sector 5, which consists of Beamlines 5.0.1, 5.0.2, and 5.0.3. Allaire came to the ALS from Brookhaven National Laboratory, where he had been responsible for macromolecular crystallography (MX) beamlines and the biological small-angle x-ray scattering (SAXS) program. Read more »
Genentech Uses ALS Crystallography for Therapeutic Antibody Research
Genentech has developed a unique one-armed antibody, onartuzumab, which is now in late-stage clinical trials in multiple cancer types. The company used crystal structures obtained at ALS Beamline 5.0.2 to demonstrate the mechanism of action of this unique potentially therapeutic antibody. Read more »
ALSNews Vol. 349
Celebrating Success and Looking Forward in Challenging Times ALS Director Roger Falcone took some time recently to reflect on the scientific and engineering accomplishments at the ALS while facing up to some of the challenges of the coming year. A difficult fiscal environment that features significant cuts in national scientific funding means that the ALSRead More Read more »